Mechanistic studies of a novel class of trisubstituted platinum(II) antitumor agents.

Chemical and biological studies are presented for a new series of platinum(II) antitumor agents that violate the classical structure-activity relationships established for platinum complexes. These new agents, which have demonstrated activity against murine and human tumor systems, are cis-[Pt(NH3)2(Am)Cl]+ cations, in which Am is a derivative of pyridine, pyrimidine, purine, or aniline. Members from this series block simian virus 40 DNA replication in vitro and inhibit the action of DNA polymerases at individual guanine residues in replication mapping experiments. Monoclonal antibodies that bind selectively to cisplatin lesions on calf thymus DNA were used in a competitive enzyme-linked immunosorbent assay study to show that the platinum-triamine complexes do not produce the type of intrastrand cross-links on DNA that are characteristics of cisplatin and analogues with the general formula cis-[Pt(amine)2X2]. These results indicate that cis-[Pt(NH3)2(Am)Cl]+ cations form monofunctional adducts on DNA rather than eliminate NH3 or Am to afford bifunctional lesions. This conclusion is further supported by nuclear magnetic resonance spectroscopic and enzymatic digestion analyses of the products of the reactions of these triamine complexes with d(GpG) and dG, which also reveal monofunctional binding. When cis-[Pt(NH3)2(4-Br-pyridine)Cl]+ was allowed to stand in phosphate-buffered saline at 37 degrees C for 14 days, however, NH4+ was released and trans-[Pt(NH3)(4-Br-pyridine)Cl2] formed concomitantly. This compound was characterized by a single crystal X-ray diffraction study, the details of which are reported. The fact that trans-[Pt(NH3)(4-Br-pyridine)Cl2] displays no anticancer activity, however, indicates that its formation from cis-[Pt(NH3)2(4-Br-pyridine)Cl]+ is not a significant component of the mechanism of action of this platinum-triamine complex. Taken together, these findings indicate that the cytotoxicity of cis-[Pt(NH3)2(Am)Cl]+ complexes most likely arises from the formation of monofunctional adducts. The DNA binding properties associated with this new class of antitumor agents suggest that they may display an activity profile different from that of cisplatin and related analogues.

[1]  C. Ghiotto,et al.  Platinum, the Synergistic Drug: From Clinical Evidence to Laboratory Suggestions , 1989 .

[2]  S. Lippard,et al.  Interaction of Platinum Antitumor Compounds with DNA , 1990 .

[3]  R. A. Speranzini,et al.  Crystal structures of trans-dichloroammine(1-methylcytosine-N3)platinum(II) hemihydrate, [PtCl2(NH3)(C5H7N3)].1/2H2O, and trans-diamminebis(1-methylcytosine-N3)platinum(II) dinitrate. Evidence for the unexpected lability of ammonia in a cis-diammineplatinum(II) complex , 1981 .

[4]  M. J. Cleare,et al.  ANTITUMOR PLATINUM COMPLEXES: STRUCTURE-ACTIVITY RELATIONSHIPS , 1980 .

[5]  B. Hartmann,et al.  Immunochemical studies of DNA modified by cis-dichlorodiammineplatinum(II) in vivo and in vitro. , 1981, Cancer research.

[6]  W. T. Bradner,et al.  TOXIC SIDE EFFECTS OF PLATINUM ANALOGS , 1980 .

[7]  R. Cramer,et al.  Evidence for diastereomers of the [platinum(N,N,N',N'-tetramethylethylenediamine)(guanosine)2]2+ cation , 1979 .

[8]  S. Ralph,et al.  Reactions of platinum(II) aqua complexes. 3. Multinuclear (nitrogen-15, platinum-195, carbon-13, and proton) NMR study of reactions of aqua and hydroxo complexes with glycine and (methylimino)diacetic acid , 1985 .

[9]  P. Tyle,et al.  Biochemical Mechanisms of Platinum Antitumor Drugs , 1987 .

[10]  S. Lippard.  Platinum, gold, and other metal chemotherapeutic agents : chemistry and biochemistry , 1983 .

[11]  D. Lane,et al.  An immunoaffinity purification procedure for SV40 large T antigen. , 1985, Virology.

[12]  S. Lippard,et al.  195Pt NMR Kinetic and Mechanistic Studies of cis- and trans-Diamminedichloroplatinum(II) Binding to DNA. , 1990 .

[13]  Katsuo,et al.  A System of Computer Programs for the Automatic Solution of Co ' sial Structures from X-ray Diffraction Data , 1993 .

[14]  E. Stern,et al.  Platinum complexes of vitamin C. NMR studies on the solution chemistry of cis-platinum(diamine)(ascorbate) complexes , 1987 .

[15]  K. Harrap,et al.  ANTITUMOR, TOXIC AND BIOCHEMICAL PROPERTIES OF CISPLATIN AND EIGHT OTHER PLATINUM COMPLEXES , 1980 .

[16]  Stephen B. Howell.  Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy , 1991, Springer US.

[17]  L S Hollis,et al.  Chemical and biological properties of a new series of cis-diammineplatinum(II) antitumor agents containing three nitrogen donors: cis-[Pt(NH3)2(N-donor)Cl]+. , 1989, Journal of medicinal chemistry.

[18]  S. Crooke,et al.  Cisplatin : current status and new developments , 1980 .

[19]  W. Hong,et al.  Chemotherapy in head and neck cancer. , 1983, The New England journal of medicine.

[20]  S. Ralph,et al.  Reactions of platinum(II) aqua complexes. 2. Platinum-195 NMR study of reactions between the tetraaquaplatinum(II) cation and chloride, hydroxide, perchlorate, nitrate, sulfate, phosphate, and acetate , 1985 .

[21]  A. Eastman.  Reevaluation of interaction of cis-dichloro(ethylenediamine)platinum(II) with DNA. , 1986, Biochemistry.

[22]  D. Fairlie,et al.  A 195Pt and 15N N.M.R. study of the anticancer drug, cis-diammine-dichloroplatinum(II), and its hydrolysis and oligomerization products , 1981 .

[23]  W. Sundquist,et al.  Monoclonal antibodies to DNA modified with cis- or trans-diamminedichloroplatinum(II). , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[24]  P. Lohman,et al.  Detection and quantification of adducts formed upon interaction of diamminedichloroplatinum (II) with DNA, by anion-exchange chromatography after enzymatic degradation. , 1982, Nucleic acids research.

[25]  G. Y. Chu,et al.  Heavy metal-nucleoside interactions. 10. Binding of cis-diammineplatinum(II) to cytidine and uridine in aqueous solution: necessary conditions for formation of platinum-uridine "blues" , 1977 .

[26]  M. Egorin,et al.  Prospective validation of a pharmacologically based dosing scheme for the cis-diamminedichloroplatinum(II) analogue diamminecyclobutanedicarboxylatoplatinum. , 1985, Cancer research.

[27]  M. Bychkov,et al.  [Chemotherapy of lung cancer]. , 1972, Voprosy onkologii.

[28]  R. Wittes.  Chemotherapy of head and neck cancer. , 1980, Otolaryngologic clinics of North America.

[29]  S. Lippard,et al.  Binding of the antitumor drug cis-diamminedichloroplatinum(II) (cisplatin) to DNA. , 1985, Biochimica et biophysica acta.

[30]  S. Lippard,et al.  Antibodies elicited against cis-diamminedichloroplatinum(II)-modified DNA are specific for cis-diamminedichloroplatinum(II)-DNA adducts formed in vivo and in vitro. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[31]  H. C. Harder,et al.  Inhibitory effects of anti‐tumor platinum compounds on DNA, RNA and protein syntheses in mammalian cells in vitro , 1970, International journal of cancer.

[32]  V. Narayanan,et al.  Synthesis, physical properties, and antitumor activity of tetraplatin and related tetrachloroplatinum(IV) stereoisomers of 1,2-diaminocyclohexane. , 1986, Cancer treatment reports.

[33]  A. Goldin,et al.  Therapeutic and pharmacological studies of tetrachloro(d,l-trans)1,2-diaminocyclohexane platinum (IV) (tetraplatin), a new platinum analogue. , 1988, Cancer research.

[34]  F. Zunino,et al.  New Cisplatin Analogues—On the Way to Better Antitumor Agents , 1987 .

[35]  B. Stillman,et al.  Replication and supercoiling of simian virus 40 DNA in cell extracts from human cells , 1985, Molecular and cellular biology.

[36]  S. Lippard,et al.  Structural aspects of platinum anticancer drug interactions with DNA , 1987 .

[37]  S. Lippard,et al.  Sequence-dependent termination of in vitro DNA synthesis by cis- and trans-diamminedichloroplatinum (II). , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[38]  S. Carter.  Cisplatin — Past, Present and Future , 1984 .

[39]  J. Barton,et al.  Binding of cis- and trans-dichlorodiammineplatinum(II) to DNA: evidence for unwinding and shortening of the double helix. , 1979, Science.

[40]  J. Dabrowiak,et al.  Platinum antitumour agents. , 1987, Progress in medicinal chemistry.

[41]  Molecular mechanics analysis of the influence of interligand interactions on isomer stabilities and barriers to isomer interconversion in diammine- and bis(amine)bis(purine)platinum(II) complexes , 1988 .

[42]  S. Lippard,et al.  Use of antibodies to probe the stereochemistry of antitumor platinum drug binding to deoxyribonucleic acid , 1983 .

[43]  W. Sundquist,et al.  Chemical And biological studies of new platinum antitumor agents , 1989 .

[44]  D. K. Treiber,et al.  Characterization of a DNA damage-recognition protein from mammalian cells that binds specifically to intrastrand d(GpG) and d(ApG) DNA adducts of the anticancer drug cisplatin. , 1990, Biochemistry.

[45]  John D. Roberts,et al.  Cisplatin Efficacy and Toxicity: Are they Separable? , 1988 .

[46]  S. Lippard,et al.  Effect of the antitumor drug cis-diamminedichloroplatinum(II) and related platinum complexes on eukaryotic DNA replication. , 1990, Biochemistry.

[47]  A. Marcelis,et al.  INTRASTRAND CROSSLINKING OF THE GUANINES OF THE DEOXYTRINUCLEOTIDE D(G-C-G) VIA CIS-DIAMMINEPLATINUM DICHLORIDE , 1982 .

[48]  J. Li,et al.  Simian virus 40 DNA replication in vitro. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[49]  G. Gale,et al.  Cis-dichlorodiammineplatinum (II). Persistent and selective inhibition of deoxyribonucleic acid synthesis in vivo. , 1970, Biochemical pharmacology.